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Thumbs-up for cancer clinical care guidelines
This dedicated AHPBA 2012 issue of HPB shows off some of the best practice and research from the 
Americas. In the United States, the National Comprehensive Cancer Network (NCCN) seeks to drive optimal 
cancer care by providing widely recognized clinical guidelines. These evidence-based guidelines are continu-
ally updated as new best evidence emerges. How well do practitioners actually use and comply with these 
guidelines? Visser et al. provide a retrospective audit examining compliance with NCCN guidelines for 
pancreatic cancer care throughout California, and reveal how compliance, and perhaps more importantly, non- 
compliance may be effecting patient outcomes. During 2001–06, 3706 patients were treated for pancreatic 
cancer at 50 large (>400 beds) California hospitals. These facilities were selected as they likely possessed the 
personnel and resources necessary to deliver multidisciplinary care. Only eight were academic centers affili-
ated with medical schools. The authors detail precisely how they measured compliance, something quite 
important given the rarity of guidelines-compliance research in the literature. Overall compliance with 
NCCN guidelines in these hospitals was disappointing indeed with only one-third of pancreatic cancer 
patients receiving compliant care. Nevertheless, the five-year survival for this entire cohort was 23%. Compli-
ant care, however, once controlled for patient and hospital factors, was associated with almost a 40% 
decreased mortality rate. If a given patient had compliant care, they enjoyed improved survival regardless 
of their cancer stage. Non-compliance could be tracked to variations in hospitals/clinical environments, 
patients factors, and to physicians and their acceptance or resistance to guidelines. With the effort and 
scrutiny put into building clinical care guidelines worldwide, especially for cancer, it might seem intuitive 
that they are broadly accepted and utilized. Well, apparently they are not, and patients may be paying the 
price for non-compliance.
Mark Callery
Sequential intra-arterial therapy followed by portal vein embolisation for 
advanced hepatic malignancy: a useful adjunct to surgery
In this issue of HPB, Peng et al. have assembled a retrospective series of patients from six major HPB units 
from around the world who have undergone sequential intra-arterial therapy (IAT) to the liver followed by 
portal vein embolisation (PVE) with the aim of inducing hypertrophy in the future liver remnant (FLR) as 
well as controlling the intra-hepatic disease. One key finding of this study was that despite a study period 
of 11 years from six major HPB units only 29 patients were indentified. This suggests that either the number 
of patients that were suitable for such an approach was relatively small or the technique has been under used 
due to clinician concern over potential morbidity. Interestingly, when compared to those patients who 
underwent either IAT or PVE therapy alone, it was clear that those undergoing dual treatment had a larger 
tumour burden as measured by tumour size. In addition, dual treated patients were more likely to have HCC 
as opposed to those in the PVE alone group which had a greater number with colorectal liver metastases 
(CRCLM). This is important as the degree of hypertrophy between these two groups was similar yet it is 
likely that the underlying ability of the FLR to regenerate was likely to be significantly greater in the PVE 
alone group and therefore the absolute effect may have been greater with dual therapy. The other key finding 
from this study was that those in the dual therapy group exhibited a significant pathological response (>50% 
tumour necrosis) to the intra-arterial therapy and this combined with the favourable 3 and 5 year survival 
figures is encouraging in terms of potentially controlling tumour growth while waiting for the FLR to 
hypertrophy or neoadjuvant therapy to be completed in the setting of CRCLM. Clearly further work will be 
required to identify those who will truly benefit from this approach but, given the shortage of organs avail-
able for transplant and the increasing indications for resection of CRCLM, this may add another string to 
the bow of the hepatic surgeon.
Saxon Connor
Centre volume & liver transplantation
Whether you like it or not, health economics are a driving force in modern healthcare design. Rationalizing 
treatments, particularly those that are very expensive, needs to be based both on cost and outcomes. In the 
study by Macomber et al. in this month’s HPB, liver transplantation outcomes and costs were investigated 
in relation to centre case volume in 63 US health care centres. What they found was that high volume centres, 
defined as those perfoming more than 75 liver transplants per year had lower morbidity and mortality rates 
than lower volume centres and were also more cost efficient. In some health care systems geography demands 
the establishment of small volume centres but in those where such issues are not so pressing it may become 
difficult to justify having higher cost and worse performing small centres in some cases in the same city as 
a high performing lower cost centre. Thankfully such decisions often lie in the hands of the regulators in 
public health care systems but in private health care systems patients may well vote with their feet if the data 
are made public. The volume debate continues and has touched just about every surgical discipline. Liver 
transplantation is often looked on as a ‘prestige programme’ and health care providers are reluctant to give 
up such practice. It will be interesting to see if this study has any influence on the size and organization of 
centres in the USA.
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